Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
出版年份 2016 全文链接
标题
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
作者
关键词
Adverse events, Guidelines, Renal cell carcinoma, Targeted therapy
出版物
BMC CANCER
Volume 16, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-02-22
DOI
10.1186/s12885-016-2084-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
- (2015) Christian Eichelberg et al. EUROPEAN UROLOGY
- A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma
- (2013) Ahmed Alasker et al. CANCER TREATMENT REVIEWS
- Selected Toxicities of Targeted Therapies: Presentation and Management
- (2013) Christian Kollmannsberger et al. SEMINARS IN ONCOLOGY
- Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
- (2012) S Bracarda et al. BRITISH JOURNAL OF CANCER
- Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents
- (2012) P. Larochelle et al. Current Oncology
- Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
- (2012) Donnette A. Dabydeen et al. EUROPEAN JOURNAL OF CANCER
- Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
- (2012) Roger B. Cohen et al. INVESTIGATIONAL NEW DRUGS
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
- (2011) Camillo Porta et al. BMC CANCER
- Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
- (2011) B. I. Rini et al. JNCI-Journal of the National Cancer Institute
- Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
- (2010) L. M. Riesenbeck et al. WORLD JOURNAL OF UROLOGY
- Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
- (2009) B. I. Levy ANNALS OF ONCOLOGY
- Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- (2009) A. Ravaud et al. ANNALS OF ONCOLOGY
- Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review
- (2009) Toni K. Choueiri et al. BJU INTERNATIONAL
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More